<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>
<body><p><u> </u></p><p><strong>15. Hepatocellular Carcinoma</strong></p><p>Hepatocellular Carcinoma (HCC) is a primary malignancy of the liver cell and must be differentiated from malignancies elsewhere that metastasize to the liver. Hepatocellular carcinoma occurs more commonly in men than in women and is often diagnosed several years after establishment of the initial causative condition. The disease has a poor prognosis resulting from metastatic or locally advanced disease. Complications include liver failure, variceal bleeding or tumour rupture with bleeding into the peritoneum. The tumour is often resistant to chemotherapy. Current strategies to prevent or treat hepatitis B and C infections and liver cirrhosis can potentially reduce the prevalence of HCC in the long term.</p><p> </p><p><strong>CAUSES</strong></p><ul><li>Cirrhosis of the liver</li><li>Alcoholic liver disease</li><li>Chronic hepatitis B virus infection</li><li>Chronic hepatitis C virus infection</li><li>Chronic exposure to hepatic carcinogens e.g. aflatoxin</li></ul><p> </p><p><strong>SYMPTOMS</strong></p><ul><li>Jaundice</li><li>Itching</li><li>Anorexia</li><li>Early satiety</li><li>Feeling of a mass in the upper abdomen</li><li>Right upper abdominal pain</li><li>Weight loss</li><li>Haematemesis</li><li>Abdominal distension</li><li>Bone pain</li><li>Dyspnoea</li></ul><p> </p><p><strong>SIGNS</strong></p><ul><li>Jaundice</li><li>Cachexia</li><li>Hepatomegaly (irregular surface, multiple nodules, may be tender)</li><li>Ascites</li><li>Hepatic bruit</li></ul><p> </p><p><strong>INVESTIGATIONS</strong></p><ul><li>FBC</li><li>LFTS</li><li>INR</li><li>Serum Alpha-Fetoprotein</li><li>Hepatitis B-Surface Antigen (HBsAg)</li><li>Hepatitis C Antibody (HCVab)</li><li>Chest X-Ray</li><li>Abdominal ultrasound scan</li><li>CT/MRI scan (if ultrasound inconclusive)</li></ul><p> </p><p><strong>TREATMENT</strong></p><p><strong>Treatment objectives </strong></p><p><strong>Curative</strong></p><ul><li>To assess for potential resectability</li></ul><p><strong>Palliative</strong></p><ul><li>To relieve pain</li><li>To relieve discomfort from gross ascites</li><li>To prevent or treat hepatic encephalopathy (See section on 'Hepatic Encephalopathy')</li></ul><p> </p><p><strong>Non-pharmacological treatment</strong></p><ul><li>Surgical resection of non-metastatic localised lesions</li><li>Paracentesis for tense ascites (See section on 'Ascites')</li><li>Supportive care (multi-vitamin supplements)</li></ul><p> </p><p><strong>Pharmacological treatment</strong></p><p><strong>A.  Pain control in patients with Hepatocellular Carcinoma</strong></p><p><strong>1st Line Treatment </strong></p><p>Evidence Rating: [B]</p><p>•  Tramadol, oral, 50 mg 12 hourly (titrate further as tolerated to de- sired effect: maximum 300 mg daily)</p><p><strong>Or</strong></p><p>•  Morphine sulphate, oral, 5-10 mg 8-12 hourly</p><p> </p><p><strong>REFERRAL CRITERIA</strong></p><p>Refer all patients with suspected HCC, especially those with small solitary lesion (&lt; 5 cm) who may be considered for percutaneous alcohol injection or surgical resection, to a specialist.</p>
</body>
</html>
